Antibe Therapeutics Inc. (ATBPF) Research

Antibe Therapeutics Inc. is a biotechnology company focused on the innovation and development of novel therapeutic solutions and medical devices. The firm operates across Canada, Europe, the United States, and other international markets, concentrating its efforts on pain management, inflammation, and regenerative medicine. A key characteristic of its pharmaceutical products is their inherent design to prevent the gastrointestinal damage and bleeding frequently associated with non-steroidal anti-inflammatory drugs (NSAIDs). Its principal compound, Otenaproxesul, is a naproxen derivative engineered to release hydrogen sulfide, and it has successfully concluded a Phase 2B gastrointestinal safety study. This compound is being developed to address a range of conditions including post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout. Furthermore, the company is advancing ATB-352, a product currently in its preclinical stage, for the treatment of acute pain. Antibe Therapeutics Inc. was founded in 2009 and is headquartered in Toronto, Canada.

Open Antibe Therapeutics Inc. (ATBPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.